CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER

CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer: a Feasibility Phase II Trial

A single-center, phase II, single-arm, feasibility study to evaluate PLD (Caelyx®) as an adjuvant chemotherapy regimen in patients with early-stage luminal B breast cancer.

The primary endpoint will be to evaluate the feasibility of adjuvant PLD (Caelyx®) for each individual subject. The regimen will be considered feasible if that subject is able to achieve relative dose intensity (RDI) of at least 85% of the 8 cycles of treatment.

Caelyx® should be administered intravenously at a dose of 20 mg/m2 once every two weeks for 8 courses.

Study Overview

• Status: Active, not recruiting
• Conditions: Breast Cancer
• Intervention / Treatment: Drug: Caelyx®

Detailed Description

In the 2011 St Gallen Consensus Conference, the Panel considered that both anthracyclines and taxanes should be included in the chemotherapy regimen for 'Luminal B' disease1. However, several patients are reluctant to receive a "strong" chemotherapy because of the fear of its toxic effects, and usually ask for a somehow "less intensive" approach, even accepting a possible reduction in the treatment efficacy.

One of the reasons why patients refuse chemotherapy more often is the fear of alopecia. Few dermatologic conditions carry as much emotional distress as chemotherapy-induced alopecia. Hair loss negatively affects a patient's perception of appearance, body image, sexuality, and self- esteem.

We decided to conduct a single-center, phase II, single-arm, feasibility study to evaluate PLD (Caelyx®) as an adjuvant chemotherapy regimen in patients with early-stage luminal B breast cancer.

The primary endpoint will be to evaluate the feasibility of adjuvant PLD (Caelyx®) for each individual subject. The regimen will be considered feasible if that subject is able to achieve relative dose intensity (RDI) of at least 85% of the 8 cycles of treatment.

Secondary endpoints will include:

• Adverse events
• Tolerability (treatment completion)
• Breast cancer free interval (BCFI; events are reappearance of invasive breast cancer at any site including contralateral disease)
• Disease Free Survival (DFS) (includes second malignancies and deaths)
• Overall survival (OS) Caelyx® should be administered intravenously at a dose of 20 mg/m2 once every two weeks for 8 courses.

• Study Type: Interventional
• Enrollment (Estimated): 63
• Phase: Phase 2

Contacts and Locations

Study Locations

• Italy
  • Milan, Italy
    • European Institute of Oncology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 68 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Performance status (ECOG) 0-2
• Operable histologically confirmed breast cancer
• Luminal B HER2-negative (ER positive, HER2 negative, and at least one of the following:

Ki- 67 'high' (≥20%) or PgR 'negative or low') or Luminal B HER2-positive (ER positive, HER2 over-expressed or amplified, any Ki-67, any PgR)

• Early-stage (pT1-3; any nodal status)
• Candidate to adjuvant chemotherapy and endocrine therapy
• The tumor must be confined to the breast and axillary nodes without detected metastases elsewhere
• Patients with synchronous (diagnosed histologically within 2 months) bilateral invasive breast cancer are eligible if all other criteria are met
• Patients must have had surgery for primary breast cancer with no known clinical residual loco-regional disease
• Margins must be negative for invasive breast cancer and DCIS
• Patients should start treatment as close to definitive surgery as possible (no later than 8 weeks)
• No prior neoadjuvant or adjuvant therapy for breast cancer. Note: Radiotherapy is allowed prior to trial entry. Raloxifene, tamoxifen, or other SERM must be discontinued at least 4 weeks before trial entry.
• No hormone replacement therapy (HRT)
• No hormonal therapy, except steroids for adrenal failure, hormones for non-breast cancer related conditions (e.g., insulin for diabetes), or intermittent dexamethasone as an antiemetic.
• No treatment with bisphosphonates, except for the treatment of osteoporosis
• Adequate bone marrow, renal, and hepatic function must be assessed within 2 months before trial entry and values must meet the following criteria:
• WBC ≥ 3.0 x 109/L
• Granulocyte count ≥ 1.500 x 109/L
• Hemoglobin ≥ 10.0 g/dL
• Platelet count ≥ 100 x 109/L
• Serum creatinine < 1.35 mg/dl - Calculated creatinine clearance at least 50 mL/min
• Serum bilirubin within normal/reference range

• AST/ALT within 1.5 x upper normal limit

  • Adequate cardiovascular function defined as the following must be assessed within 2 months before trial entry:
• LVEF ≥ 50% by echocardiography, radionuclide ventriculography or Multigated Angiography (MUGA) - No ECG evidence of acute ischemia
• No evidence of medically relevant conduction system abnormalities, which in the opinion of the investigator would preclude trial entry
• No myocardial infarction within the past 6 months
• No New York Heart Association (NYHA) class III or IV congestive heart failure
• Negative pregnancy test (in fertile women).
• Written Informed Consent (IC) must be signed and dated by the patient and the investigator prior to trial entry.
• Patients must be accessible for follow-up.
• Patients should have no psychiatric, addictive, or cognitive disorder that would prevent compliance with protocol requirements.

Exclusion Criteria:

• Patients with a history of any prior ipsilateral or contralateral invasive breast cancer.
• Patients with previous or concomitant malignancy diagnosed within the past five years. Patients with adequately treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, contra- or ipsilateral in situ breast carcinoma are eligible regardless of the date of diagnosis.
• Patients with other non-malignant uncontrolled systemic diseases that would preclude trial entry in the opinion of the investigator. Specifically not eligible are patients with uncontrolled active infection, chronic infection such as active HBV or HCV.
• Patients with myocardial infarction or pulmonary embolism within 6 months prior to trial entry.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Caelyx® for 8 courses; Caelyx® administered intravenously at a dose of 20 mg/m2 once every two weeks for 8 courses.	Drug: Caelyx®; Caelyx® every two weeks for 8 courses; Other Names: Caelyx

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Feasibility of adjuvant PLD (Caelyx®)	The regimen will be considered feasible if that subject is able to achieve relative dose intensity (RDI) of at least 85% of the 8 cycles of treatment	4 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse event	Grading for all side effects will be according to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0	4 months
percent of patient completing treatment (tolerability)	percent of patients treated according to the protocol and completing the adjuvant program, and percent protocol treatment received	4 month
Breast cancer free interval (BCFI)	BCFI is defined as the time from registration to local (including recurrence restricted to the breast after breast conserving treatment), regional, or distant relapse, or contralateral breast cancer.	5 years
Disease Free Survival (DFS)	DFS is defined as the time from registration to disease recurrence (includes second malignancies and deaths)	5 years
Overall survival (OS)	OS defined as the time from registration to death from any cause	5 years

Collaborators and Investigators

• Sponsor: European Institute of Oncology
• Collaborators: Janssen-Cilag International NV
• Investigators: Principal Investigator: Elisabetta Munzone, MD, European Institute of Oncology

Study record dates

Study Major Dates

• Study Start (Actual): March 25, 2016
• Primary Completion (Estimated): December 31, 2023
• Study Completion (Estimated): December 31, 2023

Study Registration Dates

• First Submitted: September 25, 2018
• First Submitted That Met QC Criteria: October 18, 2018
• First Posted (Actual): October 19, 2018

Study Record Updates

• Last Update Posted (Actual): September 21, 2023
• Last Update Submitted That Met QC Criteria: September 18, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Keywords: adjuvant chemotherapy; luminal B; early breast cancer
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Antibiotics, Antineoplastic; Doxorubicin; Liposomal doxorubicin
• Other Study ID Numbers: IEO 0062

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No